Physician profile
Gregory Ford
NPI 1447382874
$1,562.50
in general payments reported to CMS, 2019-2025
22 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $147 · 2021: $199 · 2022: $442 · 2023: $198 · 2024: $170 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $381.35 | 2022-2025 | Acthar |
| Allergan, INC. | $205.98 | 2020-2022 | |
| Abbvie INC. | $185.71 | 2022-2025 | |
| Alcon Vision LLC | $147.15 | 2019-2025 | Tryptyr, Argos |
| Novartis Pharmaceuticals Corporation | $102.81 | 2020-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $101.09 | 2019-2021 | |
| Omeros Corporation | $56.62 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $53.92 | 2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $48.08 | 2022-2024 | |
| Bausch & Lomb Americas INC. | $47.40 | 2023 | Vyzulta |
| Ocular Therapeutix, INC. | $36.70 | 2023 | Dextenza |
| Aerie Pharmaceuticals, INC. | $35.75 | 2019-2020 | |
| Oyster Point Pharma, INC. | $33.83 | 2022-2023 | Tyrvaya |
| Dompe US, INC. | $20.46 | 2025 | Oxervate |
| Harrow Eye, LLC | $16.27 | 2024 | Vevye |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $16.13 | 2019 | |
| New World Medical,INC. | $14.13 | 2024 | Ahmed Glaucoma Valve, Clearpath, Kahook Dual Blade |
| Novo Nordisk INC | $13.63 | 2022 | |
| Biotissue Holdings INC. | $13.14 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $12.74 | 2019 | |
| Vantage Technology LLC | $11.84 | 2022 | |
| Iridex Corporation | $7.77 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.